Drug · CHEMBL537

HYDROQUINONE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. HYDROQUINONE. Drugs and targets, record CHEMBL537. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL537

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: HYDROQUINONE; ChEMBL
ChEMBL ID: CHEMBL537; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Black and white bleaching cream, Eldopaque forte, Eldoquin forte, Hydroquinone component of tri-luma, Solaquin forte; ChEMBL
Other names: CHEBI:17594, CHEMBL537, NCI-C55834, NSC-9247; ChEMBL
DrugBank: DB09526; DrugBank
InChIKey: QIGBRXMKCJKVMJ-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 2 of its 2 diseases, from DailyMed and TTD; Open Targets

Targets0

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

None in this release.

Diseases2

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
freckles	Approval	DailyMed and TTD	63	27	https://conductscience.org/library/drugs?q=EFO_0003963
hyperpigmentation of the skin	Approval	DailyMed	2	1	https://conductscience.org/library/drugs?q=MONDO_0019289

Source Open Targets

Trials37

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00669071	Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma	Phase 4	56	2010-01-11	hydroquinone	Its name	ClinicalTrials.gov
NCT01778179	A Fixed Triple Combination Cream for Solar Lentigines Associated to Cryotherapy		50	2020-09-17	Tri-Luma	Open Targets' reading, confirmed by the trial's result groups	ClinicalTrials.gov
NCT00616239	Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women	Phase 4	20	2013-12-30	hydroquinone	Its name	ClinicalTrials.gov
NCT02977507	Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma		18	2018-11-07	hydroquinone	Its name	ClinicalTrials.gov
NCT07327983	Azelaic Acid 20% vs Hydroquinone 4% in Epidermal Melasma		146		hydroquinone	Its name	ClinicalTrials.gov
NCT06013540	Comparison Of Efficacy Of Combination Of TAM Formula Vs Kligman Formula For Melasma.	Phase 2	122		hydroquinone	Its name	ClinicalTrials.gov
NCT03585179	Oral and Topical Tranexamic Acid for the Treatment of Melasma	Phase 3	120		hydroquinone	Its name	ClinicalTrials.gov
NCT06787846	EFFICACY and TOLERABILITY of TESTED FORMULA VS. HYDROQUINONE 4% in the TREATMENT of FACIAL MELASMA		109		hydroquinone	Its name	ClinicalTrials.gov
NCT05013801	A Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma		96		hydroquinone	Its name	ClinicalTrials.gov
NCT03982849	Comparison of Topical Silymarin With Hydroquinone in the Treatment of Melasma	Phase 2	92		hydroquinone	Its name	ClinicalTrials.gov

1 to 10 of 37

See all 37 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Intense Pulsed Light (IPL) / Tri-Luma® Cream vs Intense Pulsed Light (IPL) / Inactive Control Cream: Number of Participants With Tolerability Assessments Resulting in Adverse Events	1 of 56	0 of 56	112	NCT00669071	Trial comparisons
Left Side Lytera 2.0, Right Side 4% Hydroquinone vs Left Side 4% Hydroquinone, Right Side Lytera 2.0: deaths from any cause	0 of 8	0 of 10	18	NCT02977507	Trial comparisons
Left Side Lytera 2.0, Right Side 4% Hydroquinone vs Left Side 4% Hydroquinone, Right Side Lytera 2.0: serious adverse events	1 of 8	0 of 10	18	NCT02977507	Trial comparisons

Papers from its trials17

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39369111	RESULT	1	PubMed
38896402	RESULT	1	PubMed
38192412	RESULT	1	PubMed
35357753	RESULT	1	PubMed
33849384	RESULT	1	PubMed
32856757	RESULT	1	PubMed
32649234	RESULT	1	PubMed
31502392	RESULT	1	PubMed
31354327	RESULT	1	PubMed
28748406	RESULT	1	PubMed

1 to 10 of 17

See all 17 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL537

GET https://conductscience.org/api/drugs/v1/CHEMBL537/trials?page=2

API reference For AI assistants